Biomedical subjects

S R Tolbert

Publications and source records attributed to S R Tolbert.

3 recordsLinked to original sources

PubMed1996

Selegiline in treatment of behavioral and cognitive symptoms of Alzheimer disease.

OBJECTIVE: To evaluate the effects of selegiline on behavioral and cognitive symptoms of patients with Alzheimer disease. DATA SOURCES: An English-language MEDLINE search (1982-1995) was used to identify the review articles and human clinical trials discussed in this article. STUDY SELECTION: Double- and single-blind and open-label trials were reviewed. Studies were also reviewed if selegiline was evaluated comparatively with other agents. Review articles were used for background information. DATA EXTRACTION: Data were evaluated from human studies. Studies were critiqued on the basis of design, methodology, duration, sample size, and the degree to which neuropsychological tests used in each study were compared. DATA SYNTHESIS: Selegiline is a selective, irreversible inhibitor of monoamine oxidase type B. Eight of 11 controlled trials showed selegiline had a positive effect on cognition (e.g., word fluency, delayed recall, total recall). Two of 5 controlled trials evaluating selegiline's effect on behavior (e.g., anxiety, tension, excitement, depression) showed a positive effect. CONCLUSIONS: The role of selegiline remains to be determined by large well-controlled long-term clinical trials. Selegiline may be a useful agent in managing behavioral and cognitive symptomatology associated with Alzheimer disease. Given that the management of Alzheimer disease is symptomatic and no standard treatment exists, selegiline should be considered among the various options.

Alzheimer Disease↗

PubMed1994

Pharmacologic considerations in geriatric dentistry.

Drug administration to geriatric patients in the dental office requires special care. The margin of safety, or therapeutic window, in which the drug is safely effective may be greatly decreased because of physiologic changes with age, and pharmacokinetic and pharmacodynamic alterations. Realizing that the elderly are, as a group, more susceptible to adverse drug reactions, the addition of new medications must be undertaken with caution. Consulting with the patient's physician and a close working relationship with clinical pharmacists specializing in geriatrics can facilitate safe and effective drug prescribing.

Aged↗

PubMed1991

Selegiline: initial or adjunctive therapy of Parkinson's disease?

Parkinson's disease (PD) is a progressive neurologic motor disorder. Currently, levodopa/carbidopa is the standard mode of therapy for PD; however, it does not prevent progression of the disease. Selegiline (also known as deprenyl), is a selective irreversible monoamine oxidase type B inhibitor virtually devoid of the tyramine reaction at the recommended dosage of 10 mg/d. It is approved by the Food and Drug Administration for the adjunctive use in the management of patients with PD who are receiving levodopa/carbidopa and exhibit a "wearing off" effect of levodopa. Numerous clinical trials have been conducted evaluating selegiline's role in the treatment of PD. Preliminary evidence from the DATATOP trial suggests that selegiline may slow the progression of PD when used as initial therapy. However, final results of this trial and additional long-term controlled trials comparing selegiline to levodopa and placebo groups are necessary to further clarify selegiline's role in the treatment of PD.

Clinical Trials as Topic↗